MicroRNA is involved in a number of diseases. Modulating MicroRNA technologies is vital when treating these diseases.
Mirrx Therapeutics develops a new microRNA-blocking technology based on so-called Blockmirs Blockmirs enable modulation of microRNA pathways with unprecedented precision ensuring a reduced risk of unwanted side effects. Blockmirs’ potential lies within the treatment of cancer, cardiovascular disease, immunological disease, HIV and HCV.
For further information: